Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections

COVID-19 has been affecting millions of individuals worldwide and, thus far, there is no accurate therapeutic strategy. This critical situation necessitates novel formulations for already existing, FDA approved, but poorly absorbable drug candidates, such as niclosamide (NIC), which is of great rele...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Goeun, Piao, Huiyan, Rejinold, N. Sanoj, Yu, Seungjin, Kim, Ki-yeok, Jin, Geun-woo, Choy, Jin-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160721/
https://www.ncbi.nlm.nih.gov/pubmed/34069716
http://dx.doi.org/10.3390/ph14050486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160721/
https://www.ncbi.nlm.nih.gov/pubmed/34069716
http://dx.doi.org/10.3390/ph14050486

Ejemplares similares